The price of Terns Pharmaceuticals Inc (NASDAQ: TERN) closed at $5.14 in the last session, down -1.53% from day before closing price of $5.22. On the day, 728917 shares were traded.
Ratios:
We take a closer look at TERN’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 22.39 and its Current Ratio is at 22.39. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Mizuho on June 22, 2023, initiated with a Buy rating and assigned the stock a target price of $16.
On June 07, 2023, Jefferies started tracking the stock assigning a Buy rating and target price of $18.
On May 31, 2023, ROTH MKM started tracking the stock assigning a Buy rating and target price of $23.ROTH MKM initiated its Buy rating on May 31, 2023, with a $23 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 03 ’24 when Vivo Opportunity, LLC sold 138,066 shares for $6.20 per share. The transaction valued at 856,009 led to the insider holds 268,573 shares of the business.
Vivo Opportunity, LLC sold 101,480 shares of TERN for $674,842 on Apr 02 ’24. The 10% Owner now owns 272,722 shares after completing the transaction at $6.65 per share. On Apr 01 ’24, another insider, Vivo Opportunity, LLC, who serves as the 10% Owner of the company, sold 181,117 shares for $6.99 each. As a result, the insider received 1,266,008 and left with 275,772 shares of the company.
Stock Price History:
Over the past 52 weeks, TERN has reached a high of $14.04, while it has fallen to a 52-week low of $3.26.
Shares Statistics:
A total of 64.58M shares are outstanding, with a floating share count of 41.12M. Insiders hold about 36.39% of the company’s shares, while institutions hold 76.31% stake in the company.
Earnings Estimates
The company has Geron Corporation analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $105.87, with high estimates of $42.60 and low estimates of $12.71.
Analysts are recommending an EPS of between $Basic Materials and $Energy for the fiscal current year, implying an average EPS of $Technology.
